Status:
COMPLETED
The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation
Lead Sponsor:
Mahidol University
Conditions:
Thalassemia
Eligibility:
All Genders
1-18 years
Brief Summary
Hypercoagulable state is well recognized in patients with β-thalassemia. Evidences of hypercoagulability include abnormal expression of phosphatidylserine on red blood cell (rbc) surface and consequen...
Detailed Description
Hypercoagulable state is well recognized in patients with β-thalassemia. Evidences of hypercoagulability include abnormal expression of phosphatidylserine on red blood cell (rbc) surface and consequen...
Eligibility Criteria
Inclusion
- Group 1: beta thalassemia major or beta thalassemia / Hb E who receive regular transfusion therapy (Thal- RT). The baseline Hct was more than 24% for at least 6 months.
- Group 2: beta thalassemia major or beta thalassemia / Hb E post SCT (Thal-SCT) who were discontinued immunosuppressive drugs.
- Group 3: Normal children (NC) who had normal Hb/Hct and MCV for age
Exclusion
- Children with beta thalassemia major or beta thalassemia / Hb E who have co-diseases such as immune hemolytic anemia, infection, or inflammatory diseases
Key Trial Info
Start Date :
June 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00789516
Start Date
June 1 2006
End Date
December 1 2009
Last Update
March 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pediatrics, Ramathibodi hospital
Bangkok, Thailand, 10400